August 15, 2016

Leukemia

The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email CSmith@GabrailCancerCenter.com.

Delta Fly D18-11141: Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage

Acerta ACE-CL-311: A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

PTC Therapeutics PTC299-HEM-001-LEU: Phase 1B study of PTC299 in Relapsed/Refactory Acute Leukemias

Beigene BGB-3111-216: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies

A Phase 1 First-in Human, Multi-center, open label dose-escalation study to determine the safety, tolerability Pharmacokinetics and RP2D of ABBV-184 as a single agent in subjects with previously treated cancers

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination inTreatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

A phase IB/II study of APG-2575 as a single agent or in combination with other therapeutics agents in patients with relapsed and/or refactory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (SACRED)

A phase 1B study of the pharmacokinetics, safety and efficacy of orally administered HQP1351 in subjects with refactory Chronic Myeloid Leukemia (CML)

Return to Clinical Trials at GCC